KEAP1 and diabetic kidney disease: Meanwhile, BM is an oral antioxidant and inflammation modulator, which can increase the antioxidant capacity by activating the Nrf2- Keap1-ARE signaling pathway, and slow down the development of inflammation by inhibiting the NF-κB signaling pathway, which may directly intervene in the development of diabetic kidney disease (DKD) and DR [13].